Literature DB >> 9597544

Structural comparison of fibroblast growth factor-specific heparan sulfates derived from a growing or differentiating neuroepithelial cell line.

Y G Brickman1, V Nurcombe, M D Ford, J T Gallagher, P F Bartlett, J E Turnbull.   

Abstract

Heparan sulfate (HS) glycosaminoglycans are essential modulators of fibroblast growth factor (FGF) activity both in vivo and in vitro, and appear to act by cross-linking particular forms of FGF to appropriate FGF receptors. We have recently isolated and characterized two separate HS pools derived from immortalized embryonic day 10 mouse neuroepithelial 2.3D cells: one from cells in log growth phase, which greatly potentiates the activity of FGF-2, and the other from cells undergoing contact-inhibition and differentiation, which preferentially activates FGF-1. These two pools of HS have very similar functional activities to those species isolated from primary neuroepithelial cells at corresponding stages of active proliferation or differentiation. We present here a structural comparison between these cell line HS species to establish the nature of the changes that occur in the biosynthesis of HS. A combination of chemical and enzymatic cleavage, low pressure chromatography and strong anion-exchange HPLC were used to generate full chain models of each species. Overall, the HS pools synthesized in the dividing cell line pools possessed less complex sulfation than those derived from more differentiated, growth arrested cells.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9597544     DOI: 10.1093/glycob/8.5.463

Source DB:  PubMed          Journal:  Glycobiology        ISSN: 0959-6658            Impact factor:   4.313


  9 in total

1.  Heparan sulfate-dependent signaling of fibroblast growth factor 18 by chondrocyte-derived perlecan.

Authors:  Christine Y Chuang; Megan S Lord; James Melrose; Martin D Rees; Sarah M Knox; Craig Freeman; Renato V Iozzo; John M Whitelock
Journal:  Biochemistry       Date:  2010-07-06       Impact factor: 3.162

2.  Structural and functional changes in heparan sulfate proteoglycan expression associated with the myofibroblastic phenotype.

Authors:  Gareth Thomas; Aled Clayton; Janet Thomas; Malcolm Davies; Robert Steadman
Journal:  Am J Pathol       Date:  2003-03       Impact factor: 4.307

3.  Epidermal transformation leads to increased perlecan synthesis with heparin-binding-growth-factor affinity.

Authors:  P Tapanadechopone; S Tumova; X Jiang; J R Couchman
Journal:  Biochem J       Date:  2001-04-15       Impact factor: 3.857

4.  Rapid purification and high sensitivity analysis of heparan sulfate from cells and tissues: toward glycomics profiling.

Authors:  Scott E Guimond; Tania M Puvirajesinghe; Mark A Skidmore; Ina Kalus; Thomas Dierks; Edwin A Yates; Jeremy E Turnbull
Journal:  J Biol Chem       Date:  2009-07-13       Impact factor: 5.157

Review 5.  Heparan sulfate: a key regulator of embryonic stem cell fate.

Authors:  Daniel C Kraushaar; Stephen Dalton; Lianchun Wang
Journal:  Biol Chem       Date:  2013-06       Impact factor: 3.915

6.  Syndecans in skeletal muscle development, regeneration and homeostasis.

Authors:  Addolorata Pisconti; Jennifer D Bernet; Bradley B Olwin
Journal:  Muscles Ligaments Tendons J       Date:  2012-06-17

7.  Glycomics approaches for the bioassay and structural analysis of heparin/heparan sulphates.

Authors:  Tania M Puvirajesinghe; Jeremy E Turnbull
Journal:  Metabolites       Date:  2012-11-28

8.  Glycosaminoglycan and growth factor mediated murine calvarial cell proliferation.

Authors:  Kerry J Manton; Larisa M Haupt; Kumeri Vengadasalam; Victor Nurcombe; Simon M Cool
Journal:  J Mol Histol       Date:  2007-07-25       Impact factor: 3.156

9.  Sulf1 and Sulf2 Differentially Modulate Heparan Sulfate Proteoglycan Sulfation during Postnatal Cerebellum Development: Evidence for Neuroprotective and Neurite Outgrowth Promoting Functions.

Authors:  Ina Kalus; Susanne Rohn; Tania M Puvirajesinghe; Scott E Guimond; Pieter J Eyckerman-Kölln; Gerdy Ten Dam; Toin H van Kuppevelt; Jeremy E Turnbull; Thomas Dierks
Journal:  PLoS One       Date:  2015-10-08       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.